thalidomide o amido peg c2 nh2

Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate, incorporating a cereblon ligand based on Thalidomide and a linker component commonly used in PROTAC technology.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker, incorporating a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for PROTAC technology applications.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate that combines a Thalidomide-based cereblon ligand and a linker, commonly utilized in PROTAC technology. This compound serves as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is an E3 ligase ligand-linker conjugate developed using a Thalidomide-based cereblon ligand and a 3-unit PEG linker, synthesized specifically for use in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates a cereblon ligand derived from Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating the Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment.

Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate combining a Thalidomide-based cereblon ligand with a (PROTAC) technology linker, acting as an E3 ligase ligand-linker conjugate to enable targeted protein degradation.

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.